Evidence map›Paper›PMID 26553363›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology.

Melike Ozcelik, Mesut Seker, Emrah Eraslan, Sinan Koca, Dogan Yazilitas, Ozlem Ercelep, Ersin Ozaslan, Serap Kaya, Ilhan Hacibekiroglu, Serkan Menekse and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 1 country.

Melike OzcelikDepartment of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, Istanbul, Turkey. drmelike.ozcelik@gmail.com.
Mesut SekerDepartment of Medical Oncology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey.
Emrah EraslanDepartment of Medical Oncology, Ankara Oncology Education and Research Hospital, Ankara, Turkey.
Sinan KocaDepartment of Medical Oncology, Marmara University Pendik Education and Research Hospital, Istanbul, Turkey.
Dogan YazilitasDepartment of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
Ozlem ErcelepDepartment of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, Istanbul, Turkey.
Ersin OzaslanDepartment of Medical Oncology, Erciyes University School of Medicine, Kayseri, Turkey.
Serap KayaDepartment of Medical Oncology, Marmara University Pendik Education and Research Hospital, Istanbul, Turkey.
Ilhan HacibekirogluDepartment of Medical Oncology, Trakya University School of Medicine, Edirne, Turkey.
Serkan MenekseDepartment of Medical Oncology, Celal Bayar University School of Medicine, Manisa, Turkey.
Asude AksoyDepartment of Medical Oncology, Inonu University School of Medicine, Malatya, Turkey.
Burcu Yapar TaskoyluDepartment of Medical Oncology, Pamukkale University School of Medicine, Denizli, Turkey.
Umut VarolDepartment of Medical Oncology, Izmir Katip Celebi University Atatürk Education and Research Hospital, Izmir, Turkey.
Erkan ArpaciDepartment of Medical Oncology, Sakarya University School of Medicine, Sakarya, Turkey.
Aydin CiltasDepartment of Medical Oncology, Ordu University School of Medicine, Ordu, Turkey.
Berna OksuzogluDepartment of Medical Oncology, Ankara Oncology Education and Research Hospital, Ankara, Turkey.
Nurullah ZenginDepartment of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
Mahmut GumusDepartment of Medical Oncology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey.
Mehmet AliustaogluDepartment of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, Istanbul, Turkey.
Ankara Numune Eğitim ve Araştırma Hastanesi · TRBezmiâlem Vakıf Üniversitesi · TRDr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi · TRMarmara University · TRErciyes University · TRInonu University · TRIzmir Kâtip Çelebi University · TRManisa Celal Bayar University · TROrdu University · TRPamukkale University · TRSakarya University · TRTrakya University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most data on prognostic factors for patients with high-grade undifferentiated pleomorphic sarcoma (HGUPS) is obtained from analyses of soft tissue sarcomas. The purpose of this study was to evaluate the clinicopathologic features and their impact on outcomes specifically in patients diagnosed with HGUPS. In this multicenter trial, we retrospectively analyzed 112 patients who were diagnosed and treated at 12 different institutions in Turkey. We collected data concerning the patients, tumor characteristics, and treatment modalities. There were 69 males (61.6 %) and 43 females (38.4 %). Median age was 56 years (19-90). The most common anatomic site of tumor origin was the upper extremity. Pleomorphic variant was the predominant histological subtype. Median tumor size was 8.2 cm (0.6-30 cm). Tumors were mainly deeply seated (57.1 %). Fifty-seven patients (50.9 %) were stage II and the remainder were stage III at the time of diagnosis. Median follow-up was 30 months (2-160). The primary site of distant metastasis was the lung (73.5 %) and the second most common site was the liver (11.7 %). The 5-year overall survival, distant metastasis-free survival, and local recurrence-free survival rates were 56.3, 53.4, and 67.2 %, respectively. Multivariate analysis showed that Eastern Cooperative Oncology Group (ECOG) performance score of II (p = 0.033), deep tumor location (p = 0.000), and development of distant metastasis (p = 0.004) were negatively correlated with overall survival, and perioperative radiotherapy and negative microscopic margins were significant factors for local control rates (p = 0.000 for each). Deep tumor location (p = 0.003) was the only adverse factor related to distant metastasis-free survival. Deep tumor location, ECOG performance score of II, and development of distant metastasis carry a poor prognostic implication on overall survival. These will aid clinicians in predicting survival and treatment decision.

Indexed as

PrognosisAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansLiver NeoplasmsLung NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalSarcomaUpper ExtremityHigh-grade undifferentiated pleomorphic sarcomaMalignant fibrous histiocytomaPrognostic factorsSoft tissue sarcoma

Identifiers

PMID26553363
OpenAlexW2118190570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.